Company intelligence / Profile preview

Biotherapy International

Tel Aviv, Tel Aviv District, Israelibiotherapy.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has developed innovative immunotherapy approaches, including using intentionally mismatched donor lymphocytes for cancer treatment. They have published findings in the Journal of Cancer Research and Clinical Oncology showing success with this approach. They also have experience using bone marrow, placenta and cord tissue-derived mesenchymal stromal cells (MSCs) in over 500 patients for over 10 years.

Therapeutic areas: OncologyImmunologyNeurologyOther
Modalities: ImmunotherapyCellular TherapyStem Cell TherapyMesenchymal Stem Cells (MSC)Exosomes
Industry: Biotech

Drug pipeline

1 asset

ATACK

Preclinical

Partnerships

HepC Therapeutics (Budapest, Hungary)ProBioGen (Berlin, Germany)

Beyond the preview

Go deeper on Biotherapy International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotherapy International.